US20130203671A1

US20130203671A1 - Flibanserin for the Treatment of Urinary Incontinence and Related Diseases

Info

Publication number: US20130203671A1
Application number: US13/680,722
Authority: US
Inventors: Ramiro Castro; Angelo Ceci
Original assignee: Sprout Pharmaceuticals Inc
Current assignee: Sprout Pharmaceuticals Inc
Priority date: 2006-06-30
Filing date: 2012-11-19
Publication date: 2013-08-08
Also published as: ES2336719T3; JP2009541443A; EP2037927B1; US9763936B2; US20180071282A1; US20160051545A1; WO2008000760A1; US20090312242A1; CA2654798C; CA2654798A1; EP2037927A1; US10004731B2; DE602007004615D1; ATE456369T1

Abstract

The invention relates to the use of Flibanserin for the treatment or prevention of urinary incontinence and related diseases. In a further embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment or prevention of urinary incontinence and related diseases.

Description

DESCRIPTION OF THE INVENTION

The compound 1-[2-(4-(3-trifluoromethyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one (flibanserin) is disclosed in form of its hydrochloride in European Patent Application EP-A-526434 and has the following chemical structure:
Flibanserin shows affinity for the 5-HT1A and 5-HT2-receptor. It is therefore a promising therapeutic agent for the treatment or prevention of a variety of diseases, for instance depression, schizophrenia, and anxiety.
Now, experiments provided evidence, that flibanserin can not only be used for the aforementioned diseases but also for the treatment or prevention of urinary incontinence.
In one embodiment the present invention relates to the use of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof for the manufacture of a medicament for the treatment or prevention of urinary incontinence.
With regard to the present invention the term “urinary incontinence” includes stress urinary incontinence, urge urinary incontinence, urgency, mixed urinary incontinence and overactive bladder syndrome.
Urinary Incontinence (UI), as other Lower Urinary Tract Dysfunctions, can be described as a symptom, as a sign, as an urodynamic observation or as a condition as a whole. The symptom of UI is defined as “the complaint of any involuntary leakage of urine” (Abrams P, Cardozo Neurourol Urodyn 2002; 21:167-178).
Stress urinary Incontinence (SUI) is defined as the complaint of involuntary leakage on effort or exertion, or on sneezing or coughing. It occurs because a positive urethral pressure gradient over bladder pressure cannot be maintained during abrupt increases in abdominal pressure. This insufficient urethral closure pressure can be the consequence of anatomical defects in the pelvic floor muscles leading to urethral hypermobility, intrinsic deficiency of the external urethral sphincter or a combination of both.
SUI is more prevalent in women than in men. In women pregnancy, childbirth and parity are the most important inciting factors. In men SUI is infrequent and mainly referred as a sequale after prostate surgery (Transurethral Prostate Resection for Benign Prostate Hyperplasia or Radical Prostatectomy for Prostate Cancer). Stress Urinary Incontinence is the most common type of UI in women, with 78% of women presenting with the symptom of SUI in either pure (49%) or mixed (29%) forms.
Urge urinary Incontinence (UUI) is defined as the complaint of involuntary leakage accompanied by or immediately preceded by urgency. Urgency is the complaint of a sudden compelling desire to pass urine, which may be difficult to defer.
Urge urinary incontinence is one of the symptoms which is categorised under the syndrome of Overactive Bladder (OAB). According to the ICS definition, OAB is characterised by an irresistible imperative need to urinate, which may or may not be associated with urge urinary incontinence, usually with increased frequency of micturition and nocturnal urination. Pathophysiologically, this complaint may be based on involuntary detrusor contractions during the filling phase, the cause of which may be neurogenic or non-neurogenic (idiopathic) by nature. Urgency and urge urinary incontinence are extremely unpleasant and troublesome to those affected, leading to considerable impairment of their quality of life and psychological, professional, domestic, physical and sexual problems.
Mixed urinary incontinence is defined as the complaint of involuntary leakage associated with urgency and also with exertion, effort, sneezing or coughing. Again more women are affected than men.
In another embodiment the present invention relates to the use of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof for the manufacture of a medicament for the treatment or prevention of overactive bladder syndrome.
In another embodiment the present invention relates to the use of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof for the manufacture of a medicament for the treatment or prevention of urge urinary incontinence.
In another embodiment the present invention relates to the use of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof for the manufacture of a medicament for the treatment or prevention of urgency.
In another embodiment the present invention relates to the use of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof for the manufacture of a medicament for the treatment or prevention of stress urinary incontinence.
In another embodiment the present invention relates to the use of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof for the manufacture of a medicament for the treatment or prevention of mixed urinary incontinence.
Another embodiment of the present invention relates to methods of treating or preventing of any of the aforementioned disorders, comprising the administration of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof.
As Flibanserin 1 can not only be used as a monotherapy but also in combination with other active ingredients useful for treatment of urinary incontinence, another embodiment of the invention relates to new pharmaceutical compositions comprising a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, as one active ingredient in combination with a therapeutically effective amount one or more, preferably one active ingredient 2 useful for treatment of urinary incontinence.
The compositions according to the invention may contain Flibanserin 1 and the one or more additional active ingredient 2 in a single formulation or in separate formulations (multiple dosage form). If Flibanserin 1 and the one or more, preferably one active ingredient 2 are present in separate formulations these separate formulations may be administered simultaneously or sequentially.
In a further embodiment, the present invention is directed to pharmaceutical compositions comprising a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, as one active ingredient in combination with a therapeutically effective amount of one or more, preferably one active ingredient 2 useful for treatment of urinary incontinence, wherein 2 is selected from the group consisting of antimuscarinic agents 2a, vasopressin agonists 2b, Serotonin/Noradrenaline modulators 2c and β3 agonists 2d.
In a further embodiment, the present invention is directed to pharmaceutical compositions comprising a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, as one active ingredient in combination with a therapeutically effective amount of one or more, preferably one antimuscarinic agent 2a, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof and optionally in combination with a pharmaceutical acceptable excipient. Preferred antimuscarinic agents 2a include Tolterodine, Oxybutynin, Darifenacin, Propiverine, Solifenacin and Trospium.
In a further embodiment, the present invention is directed to pharmaceutical compositions comprising a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, as one active ingredient in combination with a therapeutically effective amount of one or more, preferably one vasopressin agonist 2b, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof and optionally in combination with a pharmaceutical acceptable excipient. A preferred vasopressin agonist 2b is Desmopressin.
In a further embodiment, the present invention is directed to pharmaceutical compositions comprising a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, as one active ingredient in combination with a therapeutically effective amount of one or more, preferably one Serotonin/Noradrenaline modulator 2c, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof and optionally in combination with a pharmaceutical acceptable excipient. Preferred Serotonin/Noradrenaline modulators 2c include Venlafaxine, Duloxetine, Reboxetine and Cizoliritine.
In a further embodiment, the present invention is directed to pharmaceutical compositions comprising a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, as one active ingredient in combination with a therapeutically effective amount of one or more, preferably one β3 agonist 2d, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof and optionally in combination with a pharmaceutical acceptable excipient. Preferred β3 agonists include AD9677/TAK677, CL 316,243, SB 418790, L-796568, BMS-196085, BRL-35135A, CGP12177A, BTA-243, GW 427353, Trecanidine, Zeneca D7114, SR 59119, solabegron, CL616243, 2-[4-(2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl)phenoxy]-2-methylpropionic acid, BRL37344A and CGP-12177A
Flibanserin 1 can optionally be used in form of its pharmaceutically acceptable acid addition salts. Suitable acid addition salts include for example those of the acids selected from, succinic acid, hydrobromic acid, acetic acid, fumaric acid, maleic acid, methanesulphonic acid, lactic acid, phosphoric acid, hydrochloric acid, sulphuric acid, tartaric acid and citric acid. Mixtures of the abovementioned acid addition salts may also be used. From the aforementioned acid addition salts the hydrochloride and the hydrobromide, particularly the hydrochloride, are preferred. If flibanserin is used in form of the free base, it is preferably used in form of flibanserin polymorph A as disclosed in WO 03/014079.
The active ingredients 2 which are suitable to be combined with 1 within the teaching of the instant invention and which are mentioned hereinbefore may also be capable of forming acid addition salts with pharmaceutically acceptable acids. Representative salts include the following: Acetate, Benzenesulfonate, Benzoate, Bicarbonate, Bisulfate, Bitartrate, Borate, Bromide, Camsylate, Carbonate, Chloride, Clavulanate, Citrate, Dihydrochloride, Edetate, Edisylate, Estolate, Esylate, Fumarate, Gluceptate, Gluconate, Glutamate, Glycollylarsanilate, Hexylresorcinate, Hydrabamine, Hydrobromide, Hydrochloride, Hydroxynaphthoate, Iodide, Isothionate, Lactate, Lactobionate, Laurate, Malate, Maleate, Mandelate, Mesylate, Methylbromide, Methylnitrate, Methylsulfate, Mucate, Napsylate, Nitrate, N-methylglucamine ammonium salt, Oleate, Oxalate, Pamoate (Embonate), Palmitate, Pantothenate, Phosphate/diphosphate, Polygalacturonate, Salicylate, Stearate, Sulfate, Subacetate, Succinate, Tannate, Tartrate, Teoclate, Tosylate, Triethiodide and Valerate.
Furthermore, where the compounds 2 carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts.
The compounds 2 may have chiral centers and occur as racemates, racemic mixtures and as individual diastereomers or enantiomers with all isomeric forms being included in the present invention. Therefore, where a compound is chiral, the separate enantiomers, substantially free of the other, are included within the scope of the invention. Further included are all mixtures of the two enantiomers. Also included within the scope of the invention are polymorphs and hydrates of the compounds of the instant invention.
The present invention includes within its scope prodrugs of the compounds 1 and 2. In general, such prodrugs will be functional derivatives of the compounds of this invention which are readily convertible in vivo into the required compound.
The term “therapeutically effective amount” shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by a researcher or clinician.
As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
According to the present invention Flibanserin 1 may be administered as a monotherapy or together with component 2 as a combination therapy. If Flibanserin 1 is administered in combination with component 2, 1 and 2 may be administered separately or together in one pharmaceutical composition. In addition, the administration of one element of the combination of the present invention may be prior to, concurrent to, or subsequent to the administration of the other element of the combination.
Flibanserin 1 or the elements of the combination of 1 and 2 may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), buccal, nasal, vaginal, rectal, sublingual, or topical (e.g. ocular eyedrop) routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration.
The pharmaceutical compositions, dosage forms, kit of parts for the administration of 1 or 1 and 2 of this invention may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which is constituted of one or more accessory ingredients. In general, the pharmaceutical compositions, dosage forms, kit of parts are prepared by uniformly and intimately bringing the active ingredients into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired dosage form. In the pharmaceutical compositions the active compounds are included in an amount sufficient to produce the desired pharmacologic effect.
The pharmaceutical formulations, compositions, dosage forms or kit of parts containing 1 and/or 2, separately or together, that are suitable for oral administration may be in the form of discrete units such as hard or soft capsules, tablets, troches or lozenges, each containing a predetermined amount of the active ingredients; in the form of a dispersible powder or granules; in the form of a solution or a suspension in an aqueous liquid or non-aqueous liquid; in the form of syrups or elixirs; or in the form of an oil-in-water emulsion or a water-in-oil emulsion.
Dosage forms intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical formulations and such compositions.
The excipients used may be for example, (a) inert diluents such as mannitol, sorbitol, calcium carbonate, pregelatinized starch, lactose, calcium phosphate or sodium phosphate; (b) granulating and disintegrating agents, such as povidone, copovidone, hydroxypropylmethylcellulose, corn starch, alginic acid, crospovidone, sodiumstarchglycolate, croscarmellose, or polacrilin potassium; (c) binding agents such as microcrystalline cellulose or acacia; and (d) lubricating agents such as magnesium stearate, stearic acid, fumaric acid or talc.
In some cases, formulations for oral use may be in the form of hardgelatin or HPMC capsules wherein the active ingredients 1 and/or 2, separately or together, are mixed with an inert solid diluent, for example pregelatinized starch, calcium carbonate, calcium phosphate or kaolin, or dispensed via a pellet formulation. They may also be in the form of soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, medium chain triglycerides or olive oil.
The tablets, capsules or pellets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a delayed action or sustained action over a longer period. For example, a time delay material such as celluloseacetate phtalate or hydroxypropylcellulose acetate succinate or sustained release material such as ethylcellulose or ammoniomethacrylate copolymer (type B) may be employed.
Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number or layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, perfuming and preserving agents.
Aqueous suspensions normally contain the active materials 1 and/or 2, separately or together, in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients may be (a) suspending agents such as hydroxy ethylcellulose, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; (b) dispersing or wetting agents which may be (b.1) a naturally-occurring phosphatide such as lecithin, (b.2) a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate, (b.3) a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example heptadecaethyleneoxycetanol, (b.4) a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol such as polyoxyethylene sorbitol monooleate, or (b.5) a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride, for example polyoxyethylene sorbitan monooleate.
The aqueous suspensions may also contain one or more preservatives, for example, ethyl or n-propyl p-hydroxybenzoate; one or more coloring agents; one or more flavoring agents; and one or more sweetening agents, such as sucrose or saccharin.
Oily suspensions may be formulated by suspending the active ingredients 1 and/or 2, separately or together, in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents may be added to provide a palatable oral preparation. These compositions may be prepared by the addition of an antioxidant such as ascorbic acid.
Dispersible powders and granules are suitable for the preparation of an aqueous suspension. They provide the active ingredient 1 and/or 2, separately or together in admixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, those sweetening, flavoring and coloring agents described above may also be present.
The pharmaceutical formulations, compositions, dosage forms or kit of parts of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil such as olive oil or arachis oils, or a mineral oil such as liquid paraffin or a mixture thereof.
Suitable emulsifying agents may be (a) naturally-occurring gums such as gum acacia and gum tragacanth, (b) naturally-occurring phosphatides such as soybean and lecithin, (c) esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan monooleate, (d) condensation products of said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.
Syrups and elixirs may be formulated with sweetening agents, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a preservative and flavoring and coloring agents.
The pharmaceutical formulations, compositions, dosage forms or kit of parts containing 1 and/or 2, separately or together may be in the form of a sterile injectable aqueous or oleagenous suspension or solution. The suspension may be formulated according to known methods using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane-diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
Preparations according to this invention containing 1 and/or 2, separately or together, for parenteral administration include sterile aqueous or non-aqueous solutions, suspension, or emulsions.
Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be reconstituted in sterile water, or some other sterile injectable medium immediately before use. The combination of this invention may also be administered in the form of suppositories for rectal administration. This composition can be prepared by mixing the drugs with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter, hard fat, and polyethylene glycols. Compositions for buccal, nasal or sublingual administration are also prepared with standard excipients well known in the art.
For topical administration the formulations, compositions, dosage forms or kit of parts of this invention containing 1 and/or 2, separately or together may be formulated in liquid or semi-liquid preparations such as liniments, lotions, applications; oil-in-water or water-in-oil emulsions such as creams, ointments, jellies or pastes, including tooth-pastes; or solutions or suspensions such as drops, and the like.
The dosage of the active ingredients in the compositions of this invention may be varied. However, it is necessary that the amount of Flibanserin 1 for the administration as a monotherapy or the active ingredients 1 and 2, for the administration as a combination therapy, be such that a suitable dosage form is obtained. The selected dosage and the dosage form depend upon the desired therapeutic effect, on the route of administration and on the duration of the treatment. Dosage ranges in the combination are approximately one tenth to one times the clinically effective ranges required to induce the desired therapeutic effect, respectively when the compounds are used singly.
The beneficial effects of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, can be observed regardless of whether the disturbance existed lifelong or was acquired, and independent of etiologic origin (organic—both, physically and drug induced—, psychogen, a combination of organic—both, physically and drug induced—, and psychogen, or unknown).
Within the instant invention Flibanserin 1 is preferably administered in such an amount that per single dosage between 5 to 200 mg of Flibanserin 1 are applied. Preferred are ranges of between 10 to 150 mg, particular preferred 20 to 100 mg of Flibanserin 1. Suitable dosage forms may contain for instance 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 mg of Flibanserin 1. The aforementioned values are based on Flibanserin 1 in form of the free base. If Flibanserin 1 is applied in form of one of its acid addition salts, the corresponding values are readily calculable from the aforementioned values.
Within the instant invention the antimuscarinic agents 2a are preferably administered in such an amount that per day between 0.01 to 200 mg are applied. Preferred are ranges of between 0.5 to 100 mg, particular preferred 1 to 50 mg of the antimuscarinic agents 2a. Suitable dosage forms may contain for instance 0.01, 0.05, 0.5, 1, 2, 5, 10, 20, 25, 50, 100 or 200 mg of the antimuscarinic agents 2a. Advantageously, the compounds 2a of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
Within the instant invention the vasopressin agonist 2b are preferably administered in such an amount that per day between 0.01 to 100 mg are applied. Preferred are ranges of between 0.5 to 100 mg, particular preferred 1 to 50 mg of the vasopressin agonist 2b. Suitable dosage forms may contain for instance 0.01, 0.05, 0.5, 1, 2, 5, 10, 20, 25, 50 or 100 mg of the vasopressin agonist 2b. Advantageously, the compounds 2b of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
Within the instant invention the Serotonin/Noradrenaline modulators 2c are preferably administered in such an amount that per day between 0.1 to 200 mg are applied. Preferred are ranges of between 0.5 to 150 mg, particular preferred 1 to 100 mg of the Serotonin/Noradrenaline modulators 2c. Suitable dosage forms may contain for instance 0.1, 0.5, 1, 2, 5, 10, 20, 25, 50, 100 or 200 mg of the Serotonin/Noradrenaline modulators 2c. Advantageously, the compounds 2c of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
Within the instant invention the β3 agonists 2d are preferably administered in such an amount that per day between 0.01 to 1000 mg are applied. Preferred are ranges of between 0.1 to 500 mg, particular preferred 1 to 200 mg of the β3 agonists 2d. Suitable dosage forms may contain for instance 0.1, 0.5, 1, 2, 5, 10, 20, 25, 50, 100 or 200 mg of the β3 agonists. Advantageously, the compounds 2d of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
In another embodiment the invention relates to a method for the treatment or prevention of urinary incontinence, comprising the administration of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, in combination with a therapeutically effective amount of one or more, preferably one active ingredient 2, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, separately or together within one pharmaceutical composition.
In another embodiment the invention relates to a method for the treatment or prevention of overactive bladder syndrome, comprising the administration of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, in combination with a therapeutically effective amount of one or more, preferably one active ingredient 2, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, separately or together within one pharmaceutical composition.
In another embodiment the invention relates to a method for the treatment or prevention of urge urinary incontinence, comprising the administration of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, in combination with a therapeutically effective amount of one or more, preferably one active ingredient 2, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, separately or together within one pharmaceutical composition.
In another embodiment the invention relates to a method for the treatment or prevention of urgency, comprising the administration of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, in combination with a therapeutically effective amount of one or more, preferably one active ingredient 2, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, separately or together within one pharmaceutical composition.
In another embodiment the invention relates to a method for the treatment or prevention of stress urinary incontinence, comprising the administration of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, in combination with a therapeutically effective amount of one or more, preferably one active ingredient 2, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, separately or together within one pharmaceutical composition.
In another embodiment the invention relates to a method for the treatment or prevention of mixed urinary incontinence, comprising the administration of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, in combination with a therapeutically effective amount of one or more, preferably one active ingredient 2, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, separately or together within one pharmaceutical composition.
Another embodiment of the present invention relates to the use of the combinations of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, and of one or more, preferably one active ingredient 2, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, for the manufacture of a medicament for the treatment of any of the aforementioned disorders.
Another embodiment of the present invention relates to the use of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, for the manufacture of a medicament for the treatment of any of the aforementioned disorders in combination with one or more, preferably one active ingredient 2, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof.
In another embodiment the invention relates to a method for the treatment or prevention of one of the aforementioned diseases selected from the group consisting of urinary incontinence, overactive bladder syndrome, urge urinary incontinence, urgency, stress urinary incontinence and mixed urinary incontinence, comprising the administration of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, in combination with a therapeutically effective amount of one or more, preferably one antimuscarinic agents 2a, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, separately or together within one pharmaceutical composition. Preferred antimuscarinic agents 2a include Tolterodine, Oxybutynin, Darifenacin, Propiverine, Solifenacin and Trospium.
Another embodiment of the present invention relates to the use of the combinations of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, and of one or more, preferably one antimuscarinic agent 2a, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, for the manufacture of a medicament for the treatment of any of the aforementioned disorders. Preferred antimuscarinic agents 2a include Tolterodine, Oxybutynin, Darifenacin, Propiverine, Solifenacin and Trospium.
Another embodiment of the present invention relates to the use of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, for the manufacture of a medicament for the treatment of any of the aforementioned disorders in combination with one or more, preferably one antimuscarinic agent 2a, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof. Preferred antimuscarinic agents 2a include Tolterodine, Oxybutynin, Darifenacin, Propiverine, Solifenacin and Trospium.
In another embodiment the invention relates to a method for the treatment or prevention of one of the aforementioned diseases selected from the group consisting of urinary incontinence, overactive bladder syndrome, urge urinary incontinence, urgency, stress urinary incontinence and mixed urinary incontinence, comprising the administration of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, in combination with a therapeutically effective amount of one or more, preferably one vasopressin agonist 2b, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, separately or together within one pharmaceutical composition. A preferred vasopressin agonist 2b is Desmopressin.
Another embodiment of the present invention relates to the use of the combinations of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, and of one or more, preferably one vasopressin agonist 2b, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, for the manufacture of a medicament for the treatment of any of the aforementioned disorders. A preferred vasopressin agonist 2b is Desmopressin.
Another embodiment of the present invention relates to the use of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, for the manufacture of a medicament for the treatment of any of the aforementioned disorders in combination with one or more, preferably one vasopressin agonist 2b, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof. A preferred vasopressin agonist 2b is Desmopressin.
In another embodiment the invention relates to a method for the treatment or prevention of one of the aforementioned diseases selected from the group consisting of urinary incontinence, overactive bladder syndrome, urge urinary incontinence, urgency, stress urinary incontinence and mixed urinary incontinence, comprising the administration of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, in combination with a therapeutically effective amount of one or more, preferably one Serotonin/Noradrenaline modulator 2c, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, separately or together within one pharmaceutical composition. Preferred Serotonin/Noradrenaline modulators 2c include Venlafaxine, Duloxetine, Reboxetine and Cizoliritine.
Another embodiment of the present invention relates to the use of the combinations of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, and of one or more, preferably one Serotonin/Noradrenaline modulator 2c, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, for the manufacture of a medicament for the treatment of any of the aforementioned disorders. Preferred Serotonin/Noradrenaline modulators 2c include Venlafaxine, Duloxetine, Reboxetine and Cizoliritine.
Another embodiment of the present invention relates to the use of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, for the manufacture of a medicament for the treatment of any of the aforementioned disorders in combination with one or more, preferably one Serotonin/Noradrenaline modulator 2c, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof. Preferred Serotonin/Nor-adrenaline modulators 2c include Venlafaxine, Duloxetine, Reboxetine and Cizoliritine.
In another embodiment the invention relates to a method for the treatment or prevention of one of the aforementioned diseases selected from the group consisting of urinary incontinence, overactive bladder syndrome, urge urinary incontinence, urgency, stress urinary incontinence and mixed urinary incontinence, comprising the administration of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, in combination with a therapeutically effective amount of one or more, preferably one β3 agonist 2d, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, separately or together within one pharmaceutical composition. Preferred β3 agonists 2d include AD9677/TAK677, CL 316,243, SB 418790, L-796568, BMS-196085, BRL-35135A, CGP12177A, BTA-243, GW 427353, Trecanidine, Zeneca D7114, SR 59119, solabegron, CL616243, 2-[4-(2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl)phenoxy]-2-methylpropionic acid, BRL37344A and CGP-12177A.
Another embodiment of the present invention relates to the use of the combinations of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, and of one or more, preferably one β3 agonist 2d, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, for the manufacture of a medicament for the treatment of any of the aforementioned disorders. Preferred β3 agonists 2d include AD9677/TAK677, CL 316,243, SB 418790, L-796568, BMS-196085, BRL-35135A, CGP12177A, BTA-243, GW 427353, Trecanidine, Zeneca D7114, SR 59119, solabegron, CL616243, 2-[4-(2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl)phenoxy]-2-methylpropionic acid, BRL37344A and CGP-12177A.
Another embodiment of the present invention relates to the use of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, for the manufacture of a medicament for the treatment of any of the aforementioned disorders in combination with one or more, preferably one β3 agonist 2d, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof. Preferred β3 agonists 2d include AD9677/TAK677, CL 316,243, SB 418790, L-796568, BMS-196085, BRL-35135A, CGP12177A, BTA-243, GW 427353, Trecanidine, Zeneca D7114, SR 59119, solabegron, CL616243, 2-[4-(2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl)phenoxy]-2-methylpropionic acid, BRL37344A and CGP-12177A.
In a preferred embodiment the invention relates to a method for the treatment or prevention of overactive bladder syndrome, comprising the administration of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, in combination with a therapeutically effective amount of one or more, preferably one antimuscarinic agents 2a, selected from the group consisting of Tolterodine, Oxybutynin, Darifenacin, Propiverine, Solifenacin and Trospium, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, separately or together within one pharmaceutical composition.
Another embodiment of the present invention relates to the use of the combinations of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, and of one or more, preferably one antimuscarinic agent 2a, selected from the group consisting of Tolterodine, Oxybutynin, Darifenacin, Propiverine, Solifenacin and Trospium, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, for the manufacture of a medicament for the treatment of the overactive bladder syndrome.
Another embodiment of the present invention relates to the use of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, for the manufacture of a medicament for the treatment of overactive bladder syndrome in combination with one or more, preferably one antimuscarinic agent 2a, selected from the group consisting of Tolterodine, Oxybutynin, Darifenacin, Propiverine, Solifenacin and Trospium, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof.
In a preferred embodiment the invention relates to a method for the treatment or prevention of urge urinary incontinence, comprising the administration of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, in combination with a therapeutically effective amount of one or more, preferably one antimuscarinic agents 2a, selected from the group consisting of Tolterodine, Oxybutynin, Darifenacin, Propiverine, Solifenacin and Trospium, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, separately or together within one pharmaceutical composition.
Another embodiment of the present invention relates to the use of the combinations of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, and of one or more, preferably one antimuscarinic agent 2a, selected from the group consisting of Tolterodine, Oxybutynin, Darifenacin, Propiverine, Solifenacin and Trospium, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, for the manufacture of a medicament for the treatment of urge urinary incontinence.
Another embodiment of the present invention relates to the use of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, for the manufacture of a medicament for the treatment of urge urinary incontinence in combination with one or more, preferably one antimuscarinic agent 2a, selected from the group consisting of Tolterodine, Oxybutynin, Darifenacin, Propiverine, Solifenacin and Trospium, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof.
In a preferred embodiment the invention relates to a method for the treatment or prevention of overactive bladder syndrome, comprising the administration of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, in combination with a therapeutically effective amount of the vasopressin agonist 2b Desmopressin, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, separately or together within one pharmaceutical composition.
Another embodiment of the present invention relates to the use of the combinations of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, and of the vasopressin agonist 2b Desmopressin, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, for the manufacture of a medicament for the treatment of the overactive bladder syndrome.
Another embodiment of the present invention relates to the use of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, for the manufacture of a medicament for the treatment of the overactive bladder syndrome in combination with the vasopressin agonist 2b Desmopressin, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof.
In a preferred embodiment the invention relates to a method for the treatment or prevention of urge urinary incontinence, comprising the administration of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, in combination with a therapeutically effective amount of the vasopressin agonist 2b Desmopressin, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, separately or together within one pharmaceutical composition.
Another embodiment of the present invention relates to the use of the combinations of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, and of the vasopressin agonist 2b Desmopressin, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, for the manufacture of a medicament for the treatment of urge urinary incontinence.
Another embodiment of the present invention relates to the use of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, for the manufacture of a medicament for the treatment of urge urinary incontinence in combination with the vasopressin agonist 2b Desmopressin, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof.
In a preferred embodiment the invention relates to a method for the treatment or prevention of stress urinary incontinence, comprising the administration of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, in combination with a therapeutically effective amount of one or more, preferably one Serotonin/Noradrenaline modulator 2c, selected from the group consisting of Venlafaxine, Duloxetine, Reboxetine and Cizoliritine, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, separately or together within one pharmaceutical composition.
Another embodiment of the present invention relates to the use of the combinations of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, and of one or more, preferably one Serotonin/Noradrenaline modulator 2c, selected from the group consisting of Venlafaxine, Duloxetine, Reboxetine and Cizoliritine, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, for the manufacture of a medicament for the treatment of stress urinary incontinence.
Another embodiment of the present invention relates to the use of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, for the manufacture of a medicament for the treatment of stress urinary incontinence in combination with of one or more, preferably one Serotonin/Noradrenaline modulator 2c, selected from the group consisting of Venlafaxine, Duloxetine, Reboxetine and Cizoliritine, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof.
In a preferred embodiment the invention relates to a method for the treatment or prevention of overactive bladder syndrome, comprising the administration of a therapeutically effective amount of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, in combination with a therapeutically effective amount of one or more, preferably one β3 agonist 2d, selected from the group consisting of AD9677/TAK677, CL 316,243, SB 418790, L-796568, BMS-196085, BRL-35135A, CGP12177A, BTA-243, GW 427353, Trecanidine, Zeneca D7114, SR 59119, solabegron, CL616243, 2-[4-(2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl)phenoxy]-2-methylpropionic acid, BRL37344A and CGP-12177A, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, separately or together within one pharmaceutical composition.
Another embodiment of the present invention relates to the use of the combinations of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, and of one or more, preferably one β3 agonist 2d, selected from the group consisting of AD9677/TAK677, CL 316,243, SB 418790, L-796568, BMS-196085, BRL-35135A, CGP12177A, BTA-243, GW 427353, Trecanidine, Zeneca D7114, SR 59119, solabegron, CL616243, 2-[4-(2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl)phenoxy]-2-methylpropionic acid, BRL37344A and CGP-12177A, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, for the manufacture of a medicament for the treatment of the overactive bladder syndrome.
Another embodiment of the present invention relates to the use of Flibanserin 1, optionally in form the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, for the manufacture of a medicament for the treatment of overactive bladder syndrome in combination with one or more, preferably one β3 agonist 2d, selected from the group consisting of AD9677/TAK677, CL 316,243, SB 418790, L-796568, BMS-196085, BRL-35135A, CGP12177A, BTA-243, GW 427353, Trecanidine, Zeneca D7114, SR 59119, solabegron, CL616243, 2-[4-(2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl)phenoxy]-2-methylpropionic acid, BRL37344A and CGP-12177A, optionally in form of the pharmaceutically acceptable salts, in form of the hydrates and/or solvates and optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof.
The Examples which follow illustrate the present invention without restricting its scope:

Examples of Pharmaceutical Formulations

A)


	Tablets	per tablet

	Flibanserin	100 mg
	lactose	240 mg
	corn starch	340 mg
	polyvinylpyrrolidone	45 mg
	magnesium stearate	15 mg
		740 mg

The finely ground active substance, lactose and some of the corn starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining corn starch and the magnesium stearate are screened and mixed together. The mixture is compressed to produce tablets of suitable shape and size.

B)


	Tablets	per tablet

	Flibanserin	80 mg
	corn starch	190 mg
	lactose	55 mg
	microcrystalline cellulose	35 mg
	polyvinylpyrrolidone	15 mg
	sodium-carboxymethyl starch	23 mg
	magnesium stearate	2 mg
		400 mg

The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened. The sodium-carboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.

C)


	Coated tablets	per coated tablet

Flibanserin	5	mg
corn starch	41.5	mg
lactose	30	mg
polyvinylpyrrolidone	3	mg
magnesium stearate	0.5	mg
	80	mg

The active substance, corn starch, lactose and polyvinylpyrrolidone are thoroughly mixed and moistened with water. The moist mass is pushed through a screen with a 1 mm mesh size, dried at about 45° C. and the granules are then passed through the same screen. After the magnesium stearate has been mixed in, convex tablet cores with a diameter of 6 mm are compressed in a tablet-making machine. The tablet cores thus produced are coated in known manner with a covering consisting essentially of sugar and talc. The finished coated tablets are polished with wax.

D)


	Capsules	per capsule

Flibanserin	150	mg
Corn starch	268.5	mg
Magnesium stearate	1.5	mg
	420	mg

The substance and corn starch are mixed and moistened with water. The moist mass is screened and dried. The dry granules are screened and mixed with magnesium stearate. The finished mixture is packed into size 1 hard gelatine capsules.

E)


Ampoule solution

	Flibanserin	50 mg
	sodium chloride	50 mg
	water for inj.	5 ml

The active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic. The solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion.

F)


Suppositories

	Flibanserin	50 mg
	solid fat	1650 mg
		1700 mg

The hard fat is melted. At 40° C. the ground active substance is homogeneously dispersed. It is cooled to 38° C. and poured into slightly chilled suppository moulds.
G) Film Coated Tablet: Combination of Flibanserin with 2a


	Constituents	mg/tablet

Core

	Flibanserin	50.000
	Tolterodine	70.225
	Anhydrous dibasic calcium phosphate	100.000
	Microcrystalline cellulose	203.090
	HPMC (Methocel E5)	6.615
	Croscarmellose sodium	8.820
	Magnesium stearate	2.250

Coating

	HPMC (Methocel E5)	4.320
	Polyethylene Glycol 6000	1.260
	Titanium dioxide	1.800
	Talc	1.542
	Iron oxide red	0.078
	Total Film coated tablet	450.000

H) Film Coated Tablet: Combination of Flibanserin with 2b


	Constituents	mg/tablet

Core

	Flibanserin	50.000
	Desmopressin	10.000
	Lactose monohydrate	133.750
	Microcrystalline cellulose	40.000
	Hydroxypropylcellulose	2.500
	Corn starch	12.500
	Magnesium stearate	1.250

Coating

	HPMC (e.g. Pharmacoat 606)	2.400
	Polyethylene Glycol 6000	0.700
	Titanium dioxide	1.000
	Talc	0.857
	Iron oxide yellow	0.043
	Total Film coated tablet	255.000

I) Film coated bilayer tablet: Combination of Flibanserin with 2c


	Constituents	mg/tablet

Core

	Flibanserin	50.000
	Duloxetine	24.000
	Lactose monohydrate	143.490
	Microcrystalline cellulose	47.810
	HPMC (e.g. Pharmacoat 606)	2.500
	Carboxymethylcellulose sodium	5.000
	Mannitol	60.000
	Corn starch	36.500
	Povidone	1.000
	Colloidal silicon dioxide	1.000
	Magnesium stearate	1.700

Coating

	HPMC (e.g. Methocel E5)	3.360
	Polyethylene Glycol 6000	0.980
	Titanium dioxide	1.400
	Talc	1.200
	Iron oxide red	0.060
	Total Film coated bilayer tablet	380.000

Claims

1. A method for treating or preventing urinary incontinence comprising administering a therapeutically effective amount of Flibanserin 1, or a pharmacologically acceptable acid addition salt, hydrate, or solvate thereof.

2. The method for treating or preventing urinary incontinence according to claim 1, further comprising administering and an active ingredient 2, or a pharmaceutically acceptable salts, hydrate, or solvate thereof,

3. The method for treating or preventing urinary incontinence according to claim 1, wherein the urinary incontinence is overactive bladder syndrome

4. The method for treating or preventing urinary incontinence according to claim 2, wherein the urinary incontinence is overactive bladder syndrome.

5. The method for treating or preventing urinary incontinence according to claim 1, wherein the urinary incontinence is urgency.

6. The method for treating or preventing urinary incontinence according to claim 1, wherein the urinary incontinence is urge urinary incontinence.

7. The method for treating or preventing urinary incontinence according to claim 1, wherein the urinary incontinence is stress urinary incontinence.

8. The method for treating or preventing urinary incontinence according to claim 1, wherein the urinary incontinence is mixed urinary incontinence.

9. The method for treating or preventing urinary incontinence according to claim 2, wherein the active ingredient 2 is an antimuscarinic agent 2a, vasopressin agonist 2b, Serotonin/Noradrenaline modulator 2c, or B3 agonist 2d

10. The method for treating or preventing urinary incontinence according to claim 9, wherein the active ingredient 2 is an antimuscarinic agent 2a

11. The method for treating or preventing urinary incontinence according to claim 10, wherein the antimuscarinic agent 2a is Tolterodine, Oxybutynin, Darifenacin, Propiverine, Solifenacin, or Trospium, or a pharmaceutically acceptable acid addition salts, hydrates or solvate thereof.

12. The method for treating or preventing urinary incontinence according to claim 9, wherein the active ingredient 2 is a vasopressin agonist 2b.

13. The method for treating or preventing urinary incontinence according to claim 12, wherein the vasopressin agonists 2b is desmopressin, a pharmaceutically acceptable acid addition salt, hydrate, and/or solvate thereof.

14. The method for treating or preventing urinary incontinence according to claim 9, wherein the active ingredient 2 is a Serotonin/Noradrenaline modulator 2c.

15. The method for treating or preventing urinary incontinence according to claim 14, wherein the Serotonin/Noradrenaline modulator 2c is Venlafaxine, Duloxetine, Reboxetine, or Cizoliritine, or a pharmaceutically acceptable acid addition salts, hydrate, or solvate thereof.

16. The method for treating or preventing urinary incontinence according to claim 9, wherein the active ingredient 2 is a β3 agonist 2d.

17. The method for treating or preventing urinary incontinence according to claim 16, wherein the β3 agonist 2d is AD9677/TAK677, CL 316,243, SB 418790, L-796568, BMS-196085, BRL-35135A, CGP12177A, BTA-243, GW 427353, Trecanidine, Zeneca D7114, SR 59119, solabegron, CL616243, 2-[4-(2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl)phenoxy]-2-methylpropionic acid, BRL37344A, or CGP-12177A, or a pharmaceutically acceptable acid addition salt, hydrate, or solvate thereof.

18. A pharmaceutical composition comprising a effective amount of Flibanserin 1 as one active ingredient in combination with and a therapeutically effective amount of an active ingredient 2.

19. The pharmaceutical composition according to claim 18, wherein the active ingredient 2 is an antimuscarinic agent 2a, vasopressin agonist 2b, Serotonin/Noradrenaline modulator 2c, or B3 agonist 2d.

20. The pharmaceutical composition according to claim 19, wherein the active ingredient 2 is an antimuscarinic agent 2a.

21. The pharmaceutical composition according to claim 20, wherein the antimuscarinic agent 2a is Tolterodine, Oxybutynin, Darifenacin, Propiverine, Solifenacin, or Trospium, or a pharmaceutically acceptable acid addition salts, hydrate, or solvate thereof.

22. The pharmaceutical composition according to claim 19, wherein the active ingredient 2 is a vasopressin agonist 2b.

23. The pharmaceutical composition according to claim 22, wherein the vasopressin agonists 2b is desmopressin, or a pharmaceutically acceptable acid addition salt, hydrate, or solvate thereof.

24. The pharmaceutical composition according to claim 19, wherein the active ingredient 2 is one or more, preferably one Serotonin/Noradrenaline modulator 2c, optionally in combination with a pharmaceutically acceptable excipient.

25. The pharmaceutical composition according to claim 24, wherein the Serotonin/Noradrenaline modulator 2c is Venlafaxine, Duloxetine, Reboxetine, or Cizoliritine, optionally in form of the or a pharmaceutically acceptable acid addition salt, hydrate, or solvate thereof.

26. The pharmaceutical composition according to claim 19, wherein the active ingredient 2 is a β3 agonist 2d.

27. The pharmaceutical composition according to claim 26, wherein the β3 agonist 2d is AD9677/TAK677, CL 316,243, SB 418790, L-796568, BMS-196085, BRL-35135A, CGP12177A, BTA-243, GW 427353, Trecanidine, Zeneca D7114, SR 59119, solabegron, CL616243, 2-[4-(2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl)phenoxy]-2-methylpropionic acid, BRL37344A or CGP-12177A, or a pharmaceutically acceptable acid addition salt, the hydrate, or solvate thereof.

28.-29. (canceled)